NCT04433091View on ClinicalTrials.gov

2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

January 30, 2022

Study Completion Date

January 30, 2023

Conditions
Atrial Fibrillation
Interventions
DRUG

2-Hydroxybenzylamine

2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.

OTHER

Placebo

Placebo will be given TID for seven days prior to ablation and 28 days post ablation.

Trial Locations (1)

37232

Vanderbilt University Medical, Nashville

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Vanderbilt University Medical Center

OTHER

NCT04433091 - 2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation | Biotech Hunter | Biotech Hunter